Stockreport

Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone ...

Puma Biotechnology Inc  (PBYI) 
Last puma biotechnology inc earnings: 2/20 04:07 pm Check Earnings Report
US:NYSE Investor Relations: pumabiotechnology.com/ir.html
PDF Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cance [Read more]